(VKTX) Viking Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.306m USD | Total Return: 11.4% in 12m
Avg Turnover: 61.6M
Qual. Beats: -6
Qual. Beats: 0
Warnings
Interest Coverage Ratio -15687.4 is critical
Altman Z'' -14.49 < 1.0 - financial distress zone
Volatile
Tailwinds
No distinct edge detected
Viking Therapeutics is a San Diego-based, clinical-stage biopharmaceutical firm specializing in endocrine and metabolic disorder treatments. The company’s pipeline is centered on selective receptor agonists, notably VK2809 for non-alcoholic steatohepatitis (NASH) and VK2735, a dual GLP-1 and GIP receptor agonist targeting obesity.
The biotechnology sector typically operates on a high-risk, high-reward model where value is driven by clinical trial milestones and regulatory approvals rather than immediate revenue. Viking’s focus on the TRß receptor subtype aims to provide therapeutic benefits while minimizing systemic side effects common in non-selective treatments. Investors may find it useful to examine ValueRay for deeper technical analysis on these drug candidates.
- VK2735 clinical trial data dictates valuation within the competitive GLP-1 weight loss market
- Phase 2b VK2809 results for NASH treatment determine long-term metabolic therapy viability
- Strategic acquisition interest from major pharmaceutical companies influences short-term stock volatility
- Future capital requirements for late-stage clinical trials impact shareholder equity dilution risks
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.56 > 0.02 and ΔFCF/TA -40.50 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.56 > 3% & CFO -340.3m > Net Income -472.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.72 > 1.5 & < 3 |
| Outstanding Shares: last quarter (115.6m) vs 12m ago 3.12% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -15.7k > 6 (EBITDA TTM -501.6m / Interest Expense TTM 32.0k) |
| A: 0.83 (Total Current Assets 608.2m - Total Current Liabilities 106.3m) / Total Assets 608.2m |
| B: -1.65 (Retained Earnings -1.01b / Total Assets 608.2m) |
| C: -0.68 (EBIT TTM -502.0m / Avg Total Assets 737.6m) |
| D: -9.47 (Book Value of Equity -1.01b / Total Liabilities 106.3m) |
| Altman-Z'' = -14.49 = D |
As of May 24, 2026, the stock is trading at USD 30.68 with a total of 2,001,602 shares traded.
Over the past week, the price has changed by +2.05%,
over one month by -9.81%,
over three months by -10.36% and
over the past year by +11.40%.
Viking Therapeutics has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy VKTX.
- StrongBuy: 10
- Buy: 7
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 92.3 | 200.9% |
P/EG = -0.03
Revenue TTM = 0.0 USD
EBIT TTM = -502.0m USD
EBITDA TTM = -501.6m USD
Long Term Debt = unknown (none)
Short Term Debt = 137k USD (from shortTermDebt, last fiscal year)
Debt = 137k USD (from shortLongTermDebtTotal, last fiscal year) (leases 137k already included)
Net Debt = -602.8m USD (calculated: Debt 137k - CCE 603.0m)
Enterprise Value = 2.70b USD (3.31b + Debt 137k - CCE 603.0m)
Interest Coverage Ratio = -15.7k (Ebit TTM -502.0m / Interest Expense TTM 32.0k)
EV/FCF = -7.94x (Enterprise Value 2.70b / FCF TTM -340.3m)
FCF Yield = -12.59% (FCF TTM -340.3m / Enterprise Value 2.70b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 431k) / Revenue TTM)
Tobins Q-Ratio = 4.44 (Enterprise Value 2.70b / Total Assets 608.2m)
Interest Expense / Debt = 23.36% (Interest Expense 32.0k / Debt 137k)
Taxrate = 21.0% (US default 21%)
NOPAT = -396.6m (EBIT -502.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.72 (Total Current Assets 608.2m / Total Current Liabilities 106.3m)
Debt / Equity = 0.00 (Debt 137k / totalStockholderEquity, last quarter 501.9m)
Debt / EBITDA = 1.20 (negative EBITDA) (Net Debt -602.8m / EBITDA -501.6m)
Debt / FCF = 1.77 (negative FCF - burning cash) (Net Debt -602.8m / FCF TTM -340.3m)
Total Stockholder Equity = 662.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -64.04% (Net Income -472.3m / Total Assets 608.2m)
RoE = -28.31% (Net Income TTM -472.3m / Total Stockholder Equity 1.67b)
RoCE = -100.0% (out of range, set to none) (EBIT -502.0m / Capital Employed (Total Assets 608.2m - Current Liab 106.3m))
RoIC = -79.54% (negative operating profit) (NOPAT -396.6m / Invested Capital 498.6m)
WACC = 12.86% (E(3.31b)/V(3.31b) * Re(12.86%) + D(137k)/V(3.31b) * Rd(23.36%) * (1-Tc(0.21)))
Discount Rate = 12.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 6.59%
[DCF] Fair Price = unknown (Cash Flow -340.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.57 | # QB: -6
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.23 | Chg30d=-25.22% | Revisions=+14% | Analysts=15
EPS next Quarter (2026-09-30): EPS=-1.11 | Chg30d=-4.72% | Revisions=+14% | Analysts=15
EPS current Year (2026-12-31): EPS=-4.73 | Chg30d=-17.02% | Revisions=+14% | GrowthEPS=-48.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-4.54 | Chg30d=-1.79% | Revisions=-14% | GrowthEPS=+4.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +14%